Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?

Mint - Oct 29, 2026

Retatrutide is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro.

Read full article

More News

Science Tech Today

Provides daily Science and Technology news on scientific research with the hopes to invite and build a community to explore the multiple scientific research.

NEWSLETTER